Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thiotepa Combined With TBI, Fludarabine, and Etoposide as Intensive Pre-treatment for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory/Recurrent or High-risk Acute Leukemia: a Multi-center, Prospective, Single-arm Clinical Study

NCT07920796 is registered in ClinicalTrials.gov with Guangdong Second Provincial General Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07920796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Thiotepa Combined With TBI, Fludarabine, and Etoposide as Intensive Pre-treatment for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory/Recurrent or High-risk Acute Leukemia: a Multi-center, Prospective, Single-arm Clinical Study
Lead sponsor
Guangdong Second Provincial General Hospital
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
June 16, 2026
Completion date
July 31, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia refractory, acute leukemia, high risk, acute leukemia, relapsed

Arms

As registered; 1 arm.

  • Thiotepa/TBI/Fludarabine/Etoposide Conditioning Plus Allo-HSCT ExperimentalAllogeneic Hematopoietic Stem Cell Transplantation, Etoposide, Fludarabine, Thiotepa, Total Body Irradiation (TBI)

    Participants receive total body irradiation, thiotepa, fludarabine, and etoposide on prespecified days before their first allogeneic hematopoietic stem cell transplantation, followed by protocol-specified assessments through 24 months after transplantation.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • One-Year Disease-Free Survival Rate After Allogeneic Transplantation From date of allo-HSCT until relapse or death from any cause, assessed up to 1year.

    Proportion of participants alive without leukemia relapse at 1 year after allo-HSCT; relapse or death from any cause is an event.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • ETOPOSIDE 1 Orange Book patent
    • US RE35524; expires May 17, 2010; assignee Bristol Myers Squibb Co
  • FLUDARABINE 1 Orange Book patent
    • US 4357324; expires November 2, 2001; assignee Department of Health and Human Services
  • Thiotepa 3 Orange Book patentsPatent cliff August 16, 2041 (Orange Book patent)
    • US 11975013; expires August 16, 2041; assignee SHORLA PHARMA LTD.
    • US 12622921; expires August 16, 2041; assignee not stated
    • US 9931458; expires May 31, 2037; assignee ADIENNE PHARMA &BIOTECH SA

Lead sponsor's other trials

Guangdong Second Provincial General Hospital, most recent start first.

Similar trials

Same condition (Recurrence) and phase, most recent start first.